In AMRN filing yesterday, the below quoted is there for everyone to read:
"Based on the positive REDUCE-IT results, we have begun promoting REDUCE-IT results to healthcare professionals in the United States based on what we believe is our continuing obligation under our First Amendment settlement to ensure that our promotion of Vascepa remains truthful and non-misleading. We are also developing Vascepa for FDA approval of additional indications based on REDUCE-IT."
Market Data 
Markets 
AI
